18-06-2015 дата публикации
Номер: US20150166566A1
Принадлежит:
Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies. 2. A compound according to claim 1 , wherein R1 represents a halogen atom.3. The compound according to claim 1 , wherein R2 represents an indanyl group claim 1 , substituted or not by one or more groups selected among halogen atoms claim 1 , alkyl groups claim 1 , hydroxy claim 1 , alkoxy groups claim 1 , amino claim 1 , mono- or di-alkylamino groups claim 1 , carboxy groups claim 1 , alkyloxycarbonyl groups claim 1 , mono- or di-alkylaminocarbonyl groups claim 1 , carboxamide claim 1 , cyano claim 1 , alkylsulfonyl and trifluoromethyl groups.4. The compound according to claim 1 , wherein R2 represents an tetralinyl group claim 1 , substituted or not by one or more groups selected among halogen atoms claim 1 , alkyl groups claim 1 , hydroxy claim 1 , alkoxy groups claim 1 , amino claim 1 , mono- or di-alkylamino groups claim 1 , carboxy groups claim 1 , alkyloxycarbonyl groups claim 1 , mono- or di-alkylaminocarbonyl groups claim 1 , carboxamide claim 1 , cyano claim 1 , alkylsulfonyl and trifluoromethyl groups.5. The compound according to claim 1 , wherein R2 represents an indanyl or tetralinyl group unsubstituted or substituted by a hydroxy group.6. The compound according to claim 1 , wherein R3 represents an aryl group.7. The compound according to claim 1 , wherein R3 represents an aryl or heteroaryl group claim 1 , ...
Подробнее